Mike

Interview Transcript "I had a cough for two months, and I'd go to the doctor and get antibiotics and couldn't get over it. Finally, the fourth time I went, he did a chest x-ray. He said, 'You need to go in to have a biopsy done.' I had a biopsy done, and it was confirmed by the doctor then that I had Stage IV lung cancer.

I learned about Tarceva® (erlotinib) from my oncologist. He decided to put me on an oral drug after I had finished 16 rounds of chemotherapy and a round of pneumonia in the hospital, and I was just too weak to continue with another round of chemo. He said, 'Let's try this drug, Tarceva, and see how you respond to that.' It's gone very well.

One of my big interests is being in the garden. I like to be outside. I spend a lot of time in the garden and in the yard, and I always have. So being able to be out in the garden has been a real highlight of my life for me."

Product Indication: Tarceva is prescribed for patients with advanced-stage non-small cell lung cancer (NSCLC) who have received at least one previous chemotherapy regimen. Tarceva is not intended to be used at the same time as chemotherapy for NSCLC.

Important Safety Information:

• There have been infrequent reports of serious Interstitial Lung Disease (ILD)-like events, including fatalities, in patients receiving Tarceva for treatment of NSCLC, pancreatic cancer or other advanced solid tumors.
• Cases of hepatic failure, hepatorenal syndrome, acute renal failure (all including fatalities), and renal insufficiency have been reported during use of TARCEVA.
• In the pancreatic cancer trial, other serious adverse reactions associated with Tarceva plus gemcitabine and which may have included fatalities, were myocardial infarction/ischemia, cerebrovascular accident and microangiopathic hemolytic anemia with thrombocytopenia.
• When receiving Tarceva therapy, women should be advised against becoming pregnant or breastfeeding. Tarceva is pregnancy category D.
• The most common adverse reactions in patients with NSCLC receiving Tarceva monotherapy 150 mg were rash and diarrhea.
• The most common adverse reactions in patients with pancreatic cancer receiving Tarceva 100 mg plus gemcitabine were fatigue, rash, nausea, anorexia and diarrhea.

View full prescribing information and see the full Product Information for additional safety information.

Individual results may vary.